Keeler Thomas Management LLC Has $2.18 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Keeler Thomas Management LLC lessened its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 38.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,550 shares of the biopharmaceutical company's stock after selling 26,876 shares during the quarter. Keeler Thomas Management LLC's holdings in Bristol-Myers Squibb were worth $2,179,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in BMY. Dakota Wealth Management bought a new stake in shares of Bristol-Myers Squibb in the first quarter worth $332,000. Covestor Ltd raised its position in Bristol-Myers Squibb by 111.5% during the first quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company's stock worth $150,000 after acquiring an additional 1,082 shares in the last quarter. NewEdge Advisors LLC raised its position in Bristol-Myers Squibb by 53.2% during the first quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company's stock worth $12,075,000 after acquiring an additional 57,444 shares in the last quarter. Ergoteles LLC bought a new stake in Bristol-Myers Squibb during the first quarter worth $1,997,000. Finally, Mackenzie Financial Corp raised its position in Bristol-Myers Squibb by 25.1% during the first quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company's stock worth $24,725,000 after acquiring an additional 68,018 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

BMY has been the topic of several analyst reports. Societe Generale lowered shares of Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research report on Monday, March 11th. Bank of America lowered shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $68.00 to $60.00 in a research report on Wednesday, January 3rd. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, StockNews.com lowered shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus target price of $61.18.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock traded up $0.63 during trading hours on Friday, reaching $48.93. 10,303,913 shares of the stock were exchanged, compared to its average volume of 10,788,345. The company has a market cap of $99.17 billion, a P/E ratio of 12.68, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. Bristol-Myers Squibb has a twelve month low of $47.58 and a twelve month high of $70.93. The stock has a 50 day moving average of $51.23 and a two-hundred day moving average of $51.43.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company's revenue was up .6% compared to the same quarter last year. During the same quarter last year, the business earned $1.82 EPS. Equities analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.90%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb's payout ratio is 62.18%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.